Literature DB >> 30150427

Interaction of a Potential Anticancer Agent Hypericin and its Model Compound Emodin with DNA and Bovine Serum Albumin.

Jana Staničová1,2, Valéria Verebová3, Jiří Beneš2.   

Abstract

BACKGROUND/AIM: We report the incorporation of prospective anticancer agent hypericin into DNA and bovine serum albumin (BSA), respectively, with emphasis on comparison of the differences in interaction mode between hypericin and its model compound emodin.
MATERIALS AND METHODS: Spectrophotometric methods were used for determination of the binding constants of the drug complex with biomacromolecules. Differential scanning calorimetry was applied for evaluation of drug-macromolecule complex thermal stability.
RESULTS: The strength of interaction expressed by binding constants was found to be 4.0×104 l/mol for hypericin-DNA and 8.1×104 l/mol for emodin-DNA complex. Both molecules stabilize bovine serum albumin macromolecule and bind into the hydrophobic cavity in IIA subunit but their localization within the molecule is different.
CONCLUSION: Anticancer agent hypericin and its derivative emodin interact with DNA with medium strength and are probably incorporated into the groove of DNA by hydrogen bonds. Bovine serum albumin can serve as a transport protein for hypericin since the binding force between both molecules is adequate. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  DNA; Hypericin; emodin; interaction; serum albumins; thermal stability

Mesh:

Substances:

Year:  2018        PMID: 30150427      PMCID: PMC6199584          DOI: 10.21873/invivo.11347

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  30 in total

1.  Sequence specific interaction of the photoactive drug hypericin depends on the structural arrangement and the stability of the structure containing its specific 5AG3 target: a resonance Raman spectroscopy study.

Authors:  E Kocisová; L Chinsky; P Miskovský
Journal:  J Biomol Struct Dyn       Date:  1999-08

2.  On the value of c: can low affinity systems be studied by isothermal titration calorimetry?

Authors:  W Bruce Turnbull; Antonio H Daranas
Journal:  J Am Chem Soc       Date:  2003-12-03       Impact factor: 15.419

Review 3.  Measuring and increasing protein stability.

Authors:  C N Pace
Journal:  Trends Biotechnol       Date:  1990-04       Impact factor: 19.536

4.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

5.  Mechanism of denaturation of bovine serum albumin by dodecyl trimethylammonium bromide.

Authors:  A A Moosavi-Movahedi; A K Bordbar; A A Taleshi; H M Naderimanesh; P Ghadam
Journal:  Int J Biochem Cell Biol       Date:  1996-09       Impact factor: 5.085

Review 6.  The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work.

Authors:  R Martínez; L Chacón-García
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

7.  Isothermal titration calorimetry study of epicatechin binding to serum albumin.

Authors:  Richard A Frazier; Athina Papadopoulou; Rebecca J Green
Journal:  J Pharm Biomed Anal       Date:  2006-03-07       Impact factor: 3.935

8.  Cell-type dependent response of melanoma cells to aloe emodin.

Authors:  J Radovic; D Maksimovic-Ivanic; G Timotijevic; S Popadic; Z Ramic; V Trajkovic; D Miljkovic; S Stosic-Grujicic; S Mijatovic
Journal:  Food Chem Toxicol       Date:  2012-06-07       Impact factor: 6.023

9.  Decrease in stability of human albumin with increase in protein concentration.

Authors:  P D Ross; A Shrake
Journal:  J Biol Chem       Date:  1988-08-15       Impact factor: 5.157

10.  Studies of interaction of emodin and DNA in the presence of ethidium bromide by spectroscopic method.

Authors:  Shuyun Bi; Hanqi Zhang; Chunyu Qiao; Ying Sun; Chunming Liu
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2007-03-18       Impact factor: 4.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.